Pivonello, Rosario
Arnaldi, Giorgio
Scaroni, Carla
Giordano, Carla
Cannavò, Salvo
Iacuaniello, Davide
Trementino, Laura
Zilio, Marialuisa
Guarnotta, Valentina
Albani, Adriana
Cozzolino, Alessia
Michetti, Grazia
Boscaro, Marco
Colao, Annamaria
Article History
Received: 3 August 2018
Accepted: 12 November 2018
First Online: 9 April 2019
Conflict of interest
: R.P. has been Principal Investigator of Research Studies for Novartis; has been Co-investigator of Research Studies for Novartis, Ipsen, and Pfizer; received research grants from Novartis, Ipsen, Pfizer; has received lecturer fees and honoraria for presentations from Novartis and Shire. G.A. has been Principal Investigator of Research Studies for Novartis; received research grants from Novartis and Shire; has received speaker fees from Novartis; has received consulting fees from Novartis and Pfizer, Inc. as board Member. C.M.S. has been Principal Investigator of Research Studies for Novartis, Otsuka and Pfizer, Inc.; has been co-investigator of Research Studies for Novartis and Lilly USA, LLC; received research grants from Novartis, Lilly USA, LLC, Otsuka and Pfizer, Inc.; has been occasional consultant for Novartis and Otsuka; has received speaker fees for presentations from Otsuka and Lilly USA, LLC. C.G. has been Principal Investigator of Research Studies for Novo Nordisk and Lilly USA, LLC; received research grants from Novo Nordisk and Lilly USA, LLC; has been occasional consultant for Novartis, Pfizer, Inc., Ipsen and Shire; received speaker fees from Novo Nordisk, Lilly USA, LLC and Novartis. S.C. has been Principal Investigator of Research Studies for Novartis, Ipsen and Pfizer, Inc., received research grants from Novartis, Ipsen and Pfizer, Inc.; received honoraria speaker from Ipsen and Pfizer, Inc.; received consulting fees from Pfizer, Inc., Novartis, Shire and Eli Lilly & Company, as board Member. D.I. has nothing to disclose. L.T. received consulting fees from Novartis. M.Z. has nothing to disclose. V.G. received consulting fees from Novartis. A.A. has nothing to disclose. A. Cozzolino. received consulting fees from Novartis. G.M. has nothing to disclose. M.B. has been Principal Investigator of Research Studies for Novartis; has been Investigator of Research Studies for Novartis, HRA Pharma, ViroPharma; has received consulting fees from Novartis as board Member. A. Colao. has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Inc. and Lilly USA, LLC; has been Investigator of Research Studies for Merck & Co. and Novo Nordisk; received research grants from Novartis, Ipsen, Pfizer, Inc., Lilly USA, LLC, Merck & Co. and Novo Nordisk; has been consultant for Novartis, Ipsen and Pfizer, Inc.; received honoraria speaker from Novartis, Ipsen and Pfizer, Inc.